SCHEMBL5536764

SCHEMBL5536764

C=Cc1cccc(O)c1-c1ccn[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.50
PIM1 P11309 1/20 0.38
SCN4A P35499 1/20 0.38
HPGDS O60760 1/20 0.36
MAPT P10636 1/20 0.36
NOTUM Q6P988 3/20 0.36
CD74 P04233 1/20 0.36
MIF P14174 1/20 0.36
PDPK1 O15530 1/20 0.34
POLB P06746 1/20 0.34
CYP2E1 P05181 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2B6 P20813 1/20 0.34
AURKA O14965 1/20 0.34
CDK1 P06493 1/20 0.34
CDK2 P24941 1/20 0.34
AURKB Q96GD4 1/20 0.34
MDM2 Q00987 1/20 0.34
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923926 0.82 IDO1 (0.64) IDO1PIM1SCN4AHPGDSNOTUM
SCHEMBL5536772 0.77 IDO1 (0.64) IDO1PIM1SCN4AHPGDSNOTUM
SCHEMBL29448526 0.72 MAOA (0.42) IDO1MAPTPOLBAURKAAURKB
SCHEMBL1647470 0.70 MAOA (0.43) IDO1MAPTPOLBAURKAAURKB
SCHEMBL15094514 0.68 ALDH1A1 (0.40) MAPTPOLBCYP2B6
SCHEMBL1501845 0.67 IDO1 (1.00) IDO1PIM1SCN4AHPGDSNOTUM
SCHEMBL29998937 0.67 IDO1 (1.00) IDO1PIM1SCN4AHPGDSNOTUM
SCHEMBL27917554 0.66 IDO1 (0.96) IDO1PIM1SCN4AHPGDSNOTUM
SCHEMBL30763901 0.66 IDO1 (0.51) IDO1PIM1SCN4AMAPTPOLB
SCHEMBL19655031 0.65 MAOA (0.68) MAPTPOLBAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8710038-B2 Pyrazole kinase modulators and methods of use EXELIXIS, INC. (US) 2014-04-29 US disclosed
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use EXELIXIS, INC. (US) 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293507-A1 Pyrazole Kinase Modulators And Methods Of Use MAP3K1, MAP3K3, MAP3K5 IDO1 1615/4885PIM1 323/4885SCN4A 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.